Neurologic complications of lung cancer.
brain metastases
epidural spinal cord compression
leptomeningeal
lung cancer
Journal
Cancer
ISSN: 1097-0142
Titre abrégé: Cancer
Pays: United States
ID NLM: 0374236
Informations de publication
Date de publication:
15 10 2020
15 10 2020
Historique:
received:
03
09
2019
revised:
06
12
2019
accepted:
12
12
2019
entrez:
18
1
2021
pubmed:
19
1
2021
medline:
12
6
2021
Statut:
ppublish
Résumé
Lung cancer and its associated treatments can cause various neurologic complications, including brain and leptomeningeal metastases, epidural spinal cord compression, cerebrovascular events, and treatment-related neurotoxicities. Lung cancer care has significantly changed in the last 5 to 10 years, with novel therapies that have affected aspects of neurologic complication management. Herein, the authors review the potential neurologic complications of lung cancer, including important clinical and therapeutic aspects of care.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
4455-4465Informations de copyright
© 2020 American Cancer Society.
Références
Graus F, Dalmau J. Paraneoplastic neurological syndromes in the era of immune‐checkpoint inhibitors. Nat Rev Clin Oncol. 2019;16:535‐548.
Berzero G, Psimaras D. Neurological paraneoplastic syndromes: an update. Curr Opin Oncol. 2018;30:359‐367.
Wen PY, Loeffler JS. Management of brain metastases. Oncology (Williston Park). 1999;13:941‐954, 957‐961; discussion 961‐942, 949.
Forsyth PA, Posner JB. Headaches in patients with brain tumors: a study of 111 patients. Neurology. 1993;43:1678‐1683.
National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Non‐Small Cell Lung Cancer, V7.2019. NCCN; 2019.
National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Small Cell Lung Cancer, V2.2019. NCCN; 2019.
Oberndorfer S, Schmal T, Lohmann H, Urbanits S, Lindner K, Grisold W. [The frequency of seizures in patients with primary brain tumors or cerebral metastases. An evaluation from the Ludwig Boltzmann Institute of Neuro‐Oncology and the Department of Neurology, Kaiser Franz Josef Hospital, Vienna]. Wien Klin Wochenschr. 2002;114:911‐916.
Maschio M, Dinapoli L, Gomellini S, et al. Antiepileptics in brain metastases: safety, efficacy and impact on life expectancy. J Neurooncol. 2010;98:109‐116.
Vecht CJ, Haaxma‐Reiche H, Noordijk EM, et al. Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery? Ann Neurol. 1993;33:583‐590.
Patchell RA, Tibbs PA, Regine WF, et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA. 1998;280:1485‐1489.
Brown PD, Ballman KV, Cerhan JH, et al. Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC.3): a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol. 2017;18:1049‐1060.
Senger DR, Van de Water L, Brown LF, et al. Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev. 1993;12:303‐324.
Peters S, Camidge DR, Shaw AT, et al. Alectinib versus crizotinib in untreated ALK‐positive non‐small cell lung cancer. N Engl J Med. 2017;377:829‐838.
Novello S, Mazieres J, Oh IJ, et al. Alectinib versus chemotherapy in crizotinib‐pretreated anaplastic lymphoma kinase (ALK)‐positive non‐small cell lung cancer: results from the phase III ALUR study. Ann Oncol. 2018;29:1409‐1416.
Gainor JF, Sherman CA, Willoughby K, et al. Alectinib salvages CNS relapses in ALK‐positive lung cancer patients previously treated with crizotinib and ceritinib. J Thorac Oncol. 2015;10:232‐236.
Camidge DR, Kim HR, Ahn MJ, et al. Brigatinib versus crizotinib in ALK‐positive non‐small cell lung cancer. N Engl J Med. 2018;379:2027‐2039.
Kim DW, Tiseo M, Ahn MJ, et al. Brigatinib in patients with crizotinib‐refractory anaplastic lymphoma kinase‐positive non‐small cell lung cancer: a randomized, multicenter phase II trial. J Clin Oncol. 2017;35:2490‐2498.
Soria JC, Tan DSW, Chiari R, et al. First‐line ceritinib versus platinum‐based chemotherapy in advanced ALK‐rearranged non‐small cell lung cancer (ASCEND‐4): a randomised, open‐label, phase 3 study. Lancet. 2017;389:917‐929.
Solomon BJ, Besse B, Bauer TM, et al. Lorlatinib in patients with ALK‐positive non‐small cell lung cancer: results from a global phase 2 study. Lancet Oncol. 2018;19:1654‐1667.
Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in intreated EGFR‐mutated advanced non‐small cell lung cancer. N Engl J Med. 2018;378:113‐125.
Reungwetwattana T, Nakagawa K, Cho BC, et al. CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR‐mutated advanced non‐small cell lung cancer. J Clin Oncol. 2018;36:3290‐3297.
Schuler M, Wu YL, Hirsh V, et al. First‐line afatinib versus chemotherapy in patients with non‐small cell lung cancer and common epidermal growth factor receptor gene mutations and brain metastases. J Thorac Oncol. 2016;11:380‐390.
Wu YL, Ahn MJ, Garassino MC, et al. CNS efficacy of osimertinib in patients with T790M‐positive advanced non‐small cell lung cancer: data from a randomized phase III trial (AURA3). J Clin Oncol. 2018;36:2702‐2709.
Togashi Y, Masago K, Fukudo M, et al. Cerebrospinal fluid concentration of erlotinib and its active metabolite OSI‐420 in patients with central nervous system metastases of non‐small cell lung cancer. J Thorac Oncol. 2010;5:950‐955.
Tamiya A, Tamiya M, Nishihara T, et al. Cerebrospinal fluid penetration rate and efficacy of afatinib in patients with EGFR Mutation‐positive non‐small cell lung cancer with leptomeningeal carcinomatosis: a multicenter prospective study. Anticancer Res. 2017;37:4177‐4182.
Ballard P, Yates JW, Yang Z, et al. Preclinical comparison of osimertinib with other EGFR‐TKIs in EGFR‐mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity. Clin Cancer Res. 2016;22:5130‐5140.
Gadgeel SM, Gandhi L, Riely GJ, et al. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib‐resistant ALK‐rearranged non‐small cell lung cancer (AF‐002JG): results from the dose‐finding portion of a phase 1/2 study. Lancet Oncol. 2014;15:1119‐1128.
Costa DB, Kobayashi S, Pandya SS, et al. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol. 2011;29:e443‐e445.
Porta R, Sanchez‐Torres JM, Paz‐Ares L, et al. Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation. Eur Respir J. 2011;37:624‐631.
Doebele RC, Ahn MJ, Siena S, et al. Efficacy and safety of entrectinib in locally advanced or metastatic ROS1 fusion‐positive non‐small cell lung cancer. J Thorac Oncol. 2018;13:S321‐S322.
Drilon A, Oxnard G, Wirth L, et al. Registrational results of LIBRETTO‐001: a phase 1/2 trial of LOXO‐292 in patients with RET fusion‐positive lung cancers. J Thorac Oncol. 2019;14:S6‐S7.
Gainor JF, Lee DH, Curigliano G, et al. Clinical activity and tolerability of BLU‐667, a highly potent and selective RET inhibitor, in patients with advanced RET‐fusion+ non‐small cell lung cancer [abstract]. J Clin Oncol. 2019;37(15 suppl):9008.
Bailon O, Chouahnia K, Augier A, et al. Upfront association of carboplatin plus pemetrexed in patients with brain metastases of lung adenocarcinoma. Neuro Oncol. 2012;14:491‐495.
Goldberg SB, Gettinger SN, Mahajan A, et al. Pembrolizumab for patients with melanoma or non‐small cell lung cancer and untreated brain metastases: early analysis of a non‐randomised, open‐label, phase 2 trial. Lancet Oncol. 2016;17:976‐983.
Auperin A, Arriagada R, Pignon JP, et al. Prophylactic cranial irradiation for patients with small‐cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med. 1999;341:476‐484.
Takahashi T, Yamanaka T, Seto T, et al. Prophylactic cranial irradiation versus observation in patients with extensive‐disease small‐cell lung cancer: a multicentre, randomised, open‐label, phase 3 trial. Lancet Oncol. 2017;18:663‐671.
Cheng H, Perez‐Soler R. Leptomeningeal metastases in non‐small cell lung cancer. Lancet Oncol. 2018;19:e43‐e55.
Liao BC, Lee JH, Lin CC, et al. Epidermal growth factor receptor tyrosine kinase inhibitors for non‐small cell lung cancer patients with leptomeningeal carcinomatosis. J Thorac Oncol. 2015;10:1754‐1761.
Pavlidis N. The diagnostic and therapeutic management of leptomeningeal carcinomatosis. Ann Oncol. 2004;15(suppl 4):iv285‐iv291.
National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Central Nervous System Cancers. Version 1.2019. NCCN; 2019.
Li YS, Jiang BY, Yang JJ, et al. Leptomeningeal metastases in patients with NSCLC with EGFR mutations. J Thorac Oncol. 2016;11:1962‐1969.
Gainor JF, Ou SH, Logan J, Borges LF, Shaw AT. The central nervous system as a sanctuary site in ALK‐positive non‐small cell lung cancer. J Thorac Oncol. 2013;8:1570‐1573.
Lee SJ, Lee JI, Nam DH, et al. Leptomeningeal carcinomatosis in non‐small cell lung cancer patients: impact on survival and correlated prognostic factors. J Thorac Oncol. 2013;8:185‐191.
Yan W, Jing W, An N, et al. The clinical characteristic and prognostic factors of leptomeningeal metastasis in patients with non‐small cell lung cancer‐a retrospective study from one single cancer institute. Cancer Med. 2019;8:2769‐2776.
Choi M, Keam B, Ock CY, et al. Pemetrexed in the treatment of leptomeningeal metastasis in patients with EGFR‐mutant lung cancer. Clin Lung Cancer. 2019;20:e442‐e451.
Saboundji K, Auliac JB, Perol M, et al. Efficacy of osimertinib in EGFR‐mutated non‐small cell lung cancer with leptomeningeal metastases pretreated with EGFR‐tyrosine kinase inhibitors. Target Oncol. 2018;13:501‐507.
Solomon BJ, Bauer TM, Felip E, et al. Safety and efficacy of lorlatinib (PF‐06463922) from the dose‐escalation component of a study in patients with advanced ALK+ or ROS1+ non‐small cell lung cancer (NSCLC) [abstract]. J Clin Oncol. 2016;34(15 suppl):9009.
Gafer H, de Waard Q, Compter A, van den Heuvel M. Rapid regression of neurological symptoms in patients with metastasised ALK+ lung cancer who are treated with lorlatinib: a report of two cases. BMJ Case Rep. 2019;12:e227299.
Gaye E, Geier M, Bore P, et al. Intra‐cranial efficacy of brigatinib in an ALK‐positive non‐small cell lung cancer patient presenting leptomeningeal carcinomatosis. Lung Cancer. 2019;133:1‐3.
Kamath SD, Kumthekar PU, Kruser TJ, Mohindra NA. Intracranial response to anti‐programmed death 1 therapy in a patient with metastatic non‐small cell lung cancer with leptomeningeal carcinomatosis. Oncologist. 2018;23:e159‐e161.
El Shafie RA, Bohm K, Weber D, et al. Palliative radiotherapy for leptomeningeal carcinomatosis‐analysis of outcome, prognostic factors, and symptom response. Front Oncol. 2018;8:641.
Mitsuya K, Nakasu Y, Hayashi N, et al. Palliative cerebrospinal fluid shunting for leptomeningeal metastasis‐related hydrocephalus in patients with lung adenocarcinoma: a single‐center retrospective study. PLoS One. 2019;14:e0210074.
Mak KS, Lee LK, Mak RH, et al. Incidence and treatment patterns in hospitalizations for malignant spinal cord compression in the United States, 1998‐2006. Int J Radiat Oncol Biol Phys. 2011;80:824‐831.
Fisher CG, DiPaola CP, Ryken TC, et al. A novel classification system for spinal instability in neoplastic disease: an evidence‐based approach and expert consensus from the Spine Oncology Study Group. Spine (Phila Pa 1976). 2010;35:E1221‐E1229.
Kumar A, Weber MH, Gokaslan Z, et al. Metastatic spinal cord compression and steroid treatment: a systematic review. Clin Spine Surg. 2017;30:156‐163.
Patchell RA, Tibbs PA, Regine WF, et al. Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomized trial. Lancet. 2005;366:643‐638.
Berenson J, Pflugmacher R, Jarzem P, et al. Balloon kyphoplasty versus non‐surgical fracture management for treatment of painful vertebral body compression fractures in patients with cancer: a multicentre, randomised controlled trial. Lancet Oncol. 2011;12:225‐235.
Navi BB, Reiner AS, Kamel H, et al. Association between incident cancer and subsequent stroke. Ann Neurol. 2015;77:291‐300.
Grisold W, Oberndorfer S, Struhal W. Stroke and cancer: a review. Acta Neurol Scand. 2009;119:1‐16.
Donato J, Campigotto F, Uhlmann EJ, et al. Intracranial hemorrhage in patients with brain metastases treated with therapeutic enoxaparin: a matched cohort study. Blood. 2015;126:494‐499.
McBane RD, Wysokinski WE, Le‐Rademacher J, et al. Apixaban, dalteparin, in active cancer associated venous thromboembolism, the ADAM VTE Trial. Blood. 2018;132:421.
Srivastava G, Rana V, Wallace S, et al. Risk of intracranial hemorrhage and cerebrovascular accidents in non‐small cell lung cancer brain metastasis patients. J Thorac Oncol. 2009;4:333‐337.
DeAngelis LM, Mandell LR, Thaler HT, et al. The role of postoperative radiotherapy after resection of single brain metastases. Neurosurgery. 1989;24:798‐805.
Brown PD, Jaeckle K, Ballman KV, et al. Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: a randomized clinical trial. JAMA. 2016;316:401‐409.
Kayama T, Sato S, Sakurada K, et al. Effects of surgery with salvage stereotactic radiosurgery versus surgery with whole‐brain radiation therapy in patients with one to four brain metastases (JCOG0504): a phase III, noninferiority, randomized controlled trial. J Clin Oncol. 2018;36:3282‐3289.
Brown PD, Pugh S, Laack NN, et al. Memantine for the prevention of cognitive dysfunction in patients receiving whole‐brain radiotherapy: a randomized, double‐blind, placebo‐controlled trial. Neuro Oncol. 2013;15:1429‐1437.
Laack NN, Pugh SL, Brown PD, et al. The association of health‐related quality of life and cognitive function in patients receiving memantine for the prevention of cognitive dysfunction during whole‐brain radiotherapy. Neurooncol Pract. 2019;6:274‐282.
Gondi V, Deshmukh S, Brown PD, et al. NRG Oncology CC001: a phase III trial of hippocampal avoidance (HA) in addition to whole‐brain radiotherapy (WBRT) plus memantine to preserve neurocognitive function (NCF) in patients with brain metastases (BM). J Clin Oncol. 2019;37:2009.
Vellayappan B, Tan CL, Yong C, et al. Diagnosis and management of radiation necrosis in patients with brain metastases. Front Oncol. 2018;8:395.
Sneed PK, Mendez J, Vemer‐van den Hoek JG, et al. Adverse radiation effect after stereotactic radiosurgery for brain metastases: incidence, time course, and risk factors. J Neurosurg. 2015;123:373‐386.
Minniti G, Scaringi C, Paolini S, et al. Single‐fraction versus multifraction (3 × 9 Gy) stereotactic radiosurgery for large (>2 cm) brain metastases: a comparative analysis of local control and risk of radiation‐induced brain necrosis. Int J Radiat Oncol Biol Phys. 2016;95:1142‐1148.
Delishaj D, Ursino S, Pasqualetti F, et al. Bevacizumab for the treatment of radiation‐induced cerebral necrosis: a systematic review of the literature. J Clin Med Res. 2017;9:273‐280.
Levin VA, Bidaut L, Hou P, et al. Randomized double‐blind placebo‐controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys. 2011;79:1487‐1495.
Xu Y, Rong X, Hu W, et al. Bevacizumab monotherapy reduces radiation‐induced brain necrosis in nasopharyngeal carcinoma patients: a randomized controlled trial. Int J Radiat Oncol Biol Phys. 2018;101:1087‐1095.
DeAngelis LM, Posner JB. Neurologic Complications of Cancer. 2nd ed. Oxford University Press, Inc; 2009.
Lee EQ, Wen PY. Neurologic complications of cancer treatment with biologic agents. UpToDate. Accessed August 19, 2019. https://www.uptodate.com/contents/neurologic-complications-of-cancer-treatment-with-molecularly-targeted-and-biologic-agents
OSI Pharmaceuticals, Inc. Tarceva (erlotinib) [package insert]. OSI Pharmaceuticals, Inc; 2010.
Pfizer Laboratories. Lorbrena (lorlatinib) [package insert]. Pfizer Laboratories; 2018.
Pfizer Laboratories. Xalkori (crizotinib) [package insert]. Pfizer Laboratories; 2015.
Benentech USA, Inc. Alecensa (alectinib) [package insert]. Genentech USA, Inc; 2017.
Novartis Pharmaceuticals Corporation. Zykadia (ceritinib) [package insert]. Novartis Pharmaceuticals Corporation; 2014.
ARIAD Pharmaceuticals, Inc. Alunbrig (brigatinib) [package insert]. ARIAD Pharmaceuticals, Inc; 2017.
Ewertz M, Qvortrup C, Eckhoff L. Chemotherapy‐induced peripheral neuropathy in patients treated with taxanes and platinum derivatives. Acta Oncol. 2015;54:587‐591.
Argyriou AA, Bruna J, Genazzani AA, Cavaletti G. Chemotherapy‐induced peripheral neurotoxicity: management informed by pharmacogenetics. Nat Rev Neurol. 2017;13:492‐504.
Hershman DL, Lacchetti C, Dworkin RH, et al. Prevention and management of chemotherapy‐induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2014;32:1941‐1967.
Smith EM, Pang H, Cirrincione C, et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy‐induced painful peripheral neuropathy: a randomized clinical trial. JAMA. 2013;309:1359‐1367.
Kao JC, Liao B, Markovic SN, et al. Neurological complications associated with anti‐programmed death 1 (PD‐1) antibodies. JAMA Neurol. 2017;74:1216‐1222.
Zimmer L, Goldinger SM, Hofmann L, et al. Neurological, respiratory, musculoskeletal, cardiac and ocular side‐effects of anti‐PD‐1 therapy. Eur J Cancer. 2016;60:210‐225.
Cuzzubbo S, Javeri F, Tissier M, et al. Neurological adverse events associated with immune checkpoint inhibitors: review of the literature. Eur J Cancer. 2017;73:1‐8.
Postow MA, Sidlow R, Hellmann MD. Immune‐related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378:158‐168.
Mirabile A, Brioschi E, Ducceschi M, et al. PD‐1 Inhibitors‐related neurological toxicities in patients with non‐small cell lung cancer: a literature review. Cancers (Basel). 2019;11:E296.
Johnson DB, Manouchehri A, Haugh AM, et al. Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study. J Immunother Cancer. 2019;7:134.
Perrinjaquet C, Desbaillets N, Hottinger AF. Neurotoxicity associated with cancer immunotherapy: immune checkpoint inhibitors and chimeric antigen receptor T‐cell therapy. Curr Opin Neurol. 2019;32:500‐510.
National Comprehensive Cancer Network (NCCN). Immune Checkpoint Inhibitors‐Induced Neuromuscular Toxicity. Version 2.2019. NCCN; 2019.